A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

NCT ID: NCT04665063

Last Updated: 2020-12-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-10-22
• Study Completion Date: 2025-10-21

Brief Summary

This study is a multi-center, non-randomized, single-arm, open clinical trial.

Detailed Description

A single car consists of scFv, hinge region, transmembrane region, costimulatory domain and zeta subunit of CD3.Prior to CAR-T cell infusion, the patients will be subjected to preconditioning treatment. After CAR-T cell infusion, the patients will be evaluated for adverse reactions and efficacy.

Conditions

Hodgkin's Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Auto CAR-T

Patients will be treated with Auto CAR-T cells

Group Type: EXPERIMENTAL

Auto CAR-T

Intervention Type: BIOLOGICAL

Biological: Auto CAR-T

Cyclophosphamide,Fludarabine

Intervention Type: DRUG

Drug: Cyclophosphamide,Fludarabine

Leukapheresis

Intervention Type: PROCEDURE

Leukapheresis

Interventions

Auto CAR-T

Biological: Auto CAR-T

Intervention Type: BIOLOGICAL

Cyclophosphamide,Fludarabine

Drug: Cyclophosphamide,Fludarabine

Intervention Type: DRUG

Leukapheresis

Leukapheresis

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. Fully understand and voluntarily sign the informed consent form, and be willing and able to comply with the visits, treatment plans, laboratory inspections, and other requirements of the research as specified in the test procedure;

2. Hodgkin lymphoma patients who are judged to be relapsed/refractory by clinical diagnosis, relapse or refractory are defined as:

1. Primary resistance to standard treatment regimens;

2. Or PD occurs after standard treatment with at least second-line standard treatment plan;

3. Or the last treatment effect is SD and the duration does not exceed 6 months;

4. Or after anti-PD-1 monoclonal antibody treatment is ineffective or relapses;

5. Patients who have PD after autologous hematopoietic stem cell transplantation or confirmed recurrence by biopsy within 12 months, or patients who undergo salvage treatment after autologous hematopoietic stem cell transplantation have no remission or relapse after treatment.

3. According to RECIST version 1.1 , there should be at least one measurable tumor;

4. Subjects whose physical status scored by the Eastern Cooperative Oncology Group (ECOG) is 0~2;

5. 14 years old ≤ age ≤ 75 years old, both male and female;

6. Immunohistochemistry or flow cytometry detects tumor cells as CD30 or CD19/CD22/CD79 positive;

7. The estimated survival period from the date of signing the informed consent form is greater than 3 months;

8. Laboratory examinations meet the following conditions: hemoglobin ≥80g/L, platelet count ≥50 × 109/L, absolute neutrophil count (ANC) ≥1.0 × 109/L, if the investigator believes that the above inspection value is below the lower limit It is caused by tumor invading bone marrow and can be included in the group after consultation with the sponsor;

9. The main organ functions need to meet the following conditions: serum creatinine ≤1.5 ULN, AST (aspartate aminotransferase)/ALT (alanine aminotransferase)/ALP (alkaline phosphatase) ≤2.5 ULN, total bilirubin ≤1.5 ULN, left Ventricular ejection fraction (LVEF) ≥50%, and minimum lung function reserve (dyspnea is not higher than level 1 and blood oxygen saturation is greater than 92% under indoor conditions).

Exclusion Criteria

1. Severe cardiac insufficiency, left ventricular ejection fraction <50%;

2. There is a history of severe lung dysfunction diseases;

3. The patient has had other malignant tumors in the past 5 years, except for skin basal cell carcinoma, breast carcinoma in situ and cervical carcinoma in situ that have undergone radical treatment;

4. Combined with severe or persistent infection and cannot be effectively controlled; Severe infection: Refers to sepsis or uncontrolled infection of the infected foci, and can be included in the group after infection is controlled

5. Combined metabolic diseases (except diabetes);

6. Combined with severe autoimmune disease or innate immune deficiency;

7. Untreated active hepatitis (hepatitis B, defined as hepatitis B virus surface antigen [HBsAg] test results are positive, HBV-DNA ≥ 500 IU/ml and abnormal liver function; hepatitis C, defined as hepatitis C antibody [ HCV-Ab] positive, HCV-RNA higher than the detection limit of the analysis method and abnormal liver function) or combined with hepatitis B and C co-infection;

8. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection;

9. A history of severe allergies to biological products (including antibiotics);

10. Participate in any other clinical drug trials at the same time within one month;

11. There are other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the research, or interfere with the results of the research, and patients who the researcher believes are not suitable for participating in this research.

• Minimum Eligible Age: 14 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hebei Medical University Fourth Hospital

OTHER

Sponsor Role: collaborator

Hebei Senlang Biotechnology Inc., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Baoen Shan, PhD & MD

Role: PRINCIPAL_INVESTIGATOR

Hebei Medical University Fourth Hospital

Lihong Liu, PhD & MD

Role: PRINCIPAL_INVESTIGATOR

Hebei Medical University Fourth Hospital

Locations

Hematology Department, Hebei Medical University Fourth Hospital

Shijiazhuang, Hebei, China

Site Status: RECRUITING

Countries

China

Central Contacts

Jianqiang Li, PhD & MD

Role: CONTACT

Phone: 008615511369555

Email: limmune@gmail.com

Facility Contacts

Lihong Liu, PhD & MD

Role: primary

Other Identifiers

2020103

Identifier Type: -

Identifier Source: org_study_id